DE-BIOCORP
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS® ), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting indgår samarbejde med virksomheden Vivaldi31.10.2025 15:43:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Vivaldi, der er et globalt konsulentfirma inden for forretnings- og brandstrategi, hvilket styrker organisationens løsninger inden for strategi og forretningstransformation. Vivaldi, der blev oprettet i 1999, er kendt for sin tilgang, som forener brand, forretning og teknologi for at hjælpe kunder med at bevare deres position som markedsledere. Med aktiviteter i USA, Europa og Latinamerika samarbejder Vivaldi med nogle af verdens førende virksomheder om at styrke markedspositioner, accelerere innovation og udvikle kundecentrerede forretningsmodeller. I en tid, der er præget af hurtig forandring, drevet af kunstig intelligens, platformdynamikker og kontinuerlig fornyelse, hjælper Vivaldi sine kunder med at gentænke, hvordan forretningsværdi skabes og udnyttes. Virksomhedens tværfaglige teams kombinerer dyb indsigt i forbrugeradfærd og markedsudvikling med strategisk, kreativ og finansiel ekspertise for at levere skræddersyede løsnin
Andersen Consulting styrker sin platform gennem samarbejde med threon31.10.2025 15:35:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for forretningstransformation og digital transformation via en samarbejdsaftale med threon, der er et belgisk konsulentfirma, som er kendt for at levere pragmatisk og helhedsorienteret støtte til strategiimplementering. I mere end 20 år har threon været en vigtig rådgiver for organisationer, der ønsker at omsætte store idéer til reel forretningsmæssig effekt. Virksomheden er specialiseret i strategisk porteføljestyring, digital transformation og ledelsestræning for at hjælpe ledere med at omsætte visioner til konkret handling. threons unikke tilgang kombinerer projektlevering, udvikling af medarbejdere og intelligente softwareløsninger, hvilket giver teams mulighed for at levere hurtigere, opskalere i det rette tempo og opnå varige resultater. Tom Dedecker, CEO for threon, udtalte: "Vi skaber fokus og ro i organisationer, hvilket gør det muligt at træffe hurtigere beslutninger og gennemføre en bæredygtig transformation, der er forankre
SBC Medical to Announce Q3 2025 Financial Results on November 14 and Hold Earnings Call on November 1731.10.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it will release its Q3 2025 financial results on Friday, November 14, 2025, before the U.S. market opens. The Company will hold a Earnings Call on Monday, November 17, 2025 at 5:00 p.m. Eastern Time to discuss the financial results and take questions live. Please register in advance for the conference using the link provided below. https://edge.media-server.com/mmc/p/e2znwqtx It will automatically direct you to the registration page for “SBC Q3 2025 Financial Results Presentation.” Please follow the steps to enter your registration details and click “Submit.” Upon registration, you will be able to access the dedicated conference call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as pas
Motive Brings Seamless eSIM Activation to Luxury European Automotive Brand in Latin America31.10.2025 11:00:00 CET | Press release
Motive, a global leader in connected device lifecycle management and automation, has announced a landmark partnership with a leading operator in Central and South America, bringing seamless and secure mobile connectivity to a luxury European automotive brand’s vehicles in Mexico. The solution—powered by Motive's Entitlement Server—enables the carrier’s subscribers to link their mobile identities directly to their vehicles using embedded SIM (eSIM) technology leveraging GSMA’s mobile connectivity standards. This automotive-first for the Latin America region allows drivers to activate their mobile subscription upon entering a vehicle, delivering a personalized, connected experience on par with their smartphones. Whether for entertainment, navigation, or communication services, users benefit from uninterrupted access to their mobile services with enhanced security and privacy. "This deployment showcases the power of intelligent entitlement and provisioning," said Francisco Viana, VP Sales
Hanshow and Unide Partner to Advance Store Modernization under the “Plan Unide 2.0” Strategy31.10.2025 02:45:00 CET | Press release
Hanshow, a global leader in digital retail solutions, has announced a strategic collaboration with Unide Corporativa, one of Spain’s most established food retail cooperatives, to advance store digitalization and operational efficiency under its new strategic roadmap “Plan Unide 2.0” (2025–2028). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030921658/en/ Founded over 90 years ago, Unide unites hundreds of independent grocery retailers across Spain under a cooperative model built on proximity, freshness, and community service. With Plan Unide 2.0, the cooperative aims to strengthen competitiveness through member business development, store modernization, and new store openings—a roadmap to ensure sustainable growth in an evolving retail landscape. Unide faces operational challenges common to cooperative retail: manual paper label updates, inconsistent pricing, and limited promotional agility across its network. Meanwhile,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom